These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 15388253)
21. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770 [TBL] [Abstract][Full Text] [Related]
22. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. Tang L; Zhu Q; Qin E; Yu M; Ding Z; Shi H; Cheng X; Wang C; Chang G; Zhu Q; Fang F; Chang H; Li S; Zhang X; Chen X; Yu J; Wang J; Chen Z DNA Cell Biol; 2004 Jun; 23(6):391-4. PubMed ID: 15231072 [TBL] [Abstract][Full Text] [Related]
23. A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro. Wang X; Xu W; Tong D; Ni J; Gao H; Wang Y; Chu Y; Li P; Yang X; Xiong S Immunol Lett; 2008 Aug; 119(1-2):71-7. PubMed ID: 18533276 [TBL] [Abstract][Full Text] [Related]
24. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model. Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090 [TBL] [Abstract][Full Text] [Related]
25. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. Bolles M; Deming D; Long K; Agnihothram S; Whitmore A; Ferris M; Funkhouser W; Gralinski L; Totura A; Heise M; Baric RS J Virol; 2011 Dec; 85(23):12201-15. PubMed ID: 21937658 [TBL] [Abstract][Full Text] [Related]
26. [Potent neutralization antibody elicited in mice by SARS-associated coronavirus spike protein S1 domain]. Zhang Y; Yang F; Li YH; Li WH; Tu XM; Wei Q; Zhu H; Liu L; Wang H; Qin C; Yuan GY; He W; Wang SH Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):258-60. PubMed ID: 15640862 [TBL] [Abstract][Full Text] [Related]
27. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Yang ZY; Kong WP; Huang Y; Roberts A; Murphy BR; Subbarao K; Nabel GJ Nature; 2004 Apr; 428(6982):561-4. PubMed ID: 15024391 [TBL] [Abstract][Full Text] [Related]
28. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. He Y; Zhou Y; Wu H; Luo B; Chen J; Li W; Jiang S J Immunol; 2004 Sep; 173(6):4050-7. PubMed ID: 15356154 [TBL] [Abstract][Full Text] [Related]
29. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice. Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640 [TBL] [Abstract][Full Text] [Related]
30. Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Ishii K; Hasegawa H; Nagata N; Mizutani T; Morikawa S; Suzuki T; Taguchi F; Tashiro M; Takemori T; Miyamura T; Tsunetsugu-Yokota Y Virology; 2006 Aug; 351(2):368-80. PubMed ID: 16678878 [TBL] [Abstract][Full Text] [Related]
31. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615 [TBL] [Abstract][Full Text] [Related]
32. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500 [TBL] [Abstract][Full Text] [Related]
33. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Liu SJ; Leng CH; Lien SP; Chi HY; Huang CY; Lin CL; Lian WC; Chen CJ; Hsieh SL; Chong P Vaccine; 2006 Apr; 24(16):3100-8. PubMed ID: 16494977 [TBL] [Abstract][Full Text] [Related]
34. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Lv H; Wu NC; Tsang OT; Yuan M; Perera RAPM; Leung WS; So RTY; Chan JMC; Yip GK; Chik TSH; Wang Y; Choi CYC; Lin Y; Ng WW; Zhao J; Poon LLM; Peiris JSM; Wilson IA; Mok CKP Cell Rep; 2020 Jun; 31(9):107725. PubMed ID: 32426212 [TBL] [Abstract][Full Text] [Related]
35. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Takasuka N; Fujii H; Takahashi Y; Kasai M; Morikawa S; Itamura S; Ishii K; Sakaguchi M; Ohnishi K; Ohshima M; Hashimoto S; Odagiri T; Tashiro M; Yoshikura H; Takemori T; Tsunetsugu-Yokota Y Int Immunol; 2004 Oct; 16(10):1423-30. PubMed ID: 15314040 [TBL] [Abstract][Full Text] [Related]
36. Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. Pei H; Liu J; Cheng Y; Sun C; Wang C; Lu Y; Ding J; Zhou J; Xiang H Appl Microbiol Biotechnol; 2005 Aug; 68(2):220-7. PubMed ID: 15660214 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine. Luo F; Liao FL; Wang H; Tang HB; Yang ZQ; Hou W Virol Sin; 2018 Apr; 33(2):201-204. PubMed ID: 29541941 [No Abstract] [Full Text] [Related]
38. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515 [TBL] [Abstract][Full Text] [Related]
39. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. He Y; Li J; Du L; Yan X; Hu G; Zhou Y; Jiang S Vaccine; 2006 Jun; 24(26):5498-508. PubMed ID: 16725238 [TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. Li J; Ulitzky L; Silberstein E; Taylor DR; Viscidi R Viral Immunol; 2013 Apr; 26(2):126-32. PubMed ID: 23573979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]